Zoetis Beats Q2 Estimates On Strong U.S. Pet-Care Sales

Shares of animal-health giant Zoetis (ZTS) rose to a 13-month high in early trading Wednesday after the company beat Q2 estimates and modestly raised its guidance.

Earnings grew 14% over the year-earlier quarter and beat analysts' consensus by 11%, while sales rose 3% and topped estimates by 3%. Zoetis' U.S. pet-care business did especially well, with 17% growth, helped by the canine itching treatment Apoquel, as well as the newly approved oral flea killer Simparica. International growth...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Zoetis [+]    ZTS [+]    Apoquel [+]    Simparica [+]   

More #news: